SLC6A3 and HIV-associated neurocognitive disorder: Considering that site-directed mutagenesis studies on DAT typically result in a decrease in DA uptake35, 37, 57, 58, the enhancement of DA transporter as evidenced by the H547A mutant suggests that targeting this residue may provide an exciting knowledge basis for the development of novel concepts for the therapeutic treatment of the HAND.